Amarantus BioScience Holdings, Inc.
AMBS · OTC
3/31/2023 | 12/31/2022 | 9/30/2022 | 6/30/2022 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $0 | $0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -94.5% | -61.8% | 449.7% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 100% | 100% | 100% | 100% |
| EBITDA | -$0 | -$0 | $0 | -$0 |
| % Margin | -4,705.9% | -5,794.4% | 596.6% | -4,928.5% |
| Net Income | -$0 | -$0 | $0 | -$0 |
| % Margin | -4,080.5% | -6,029.9% | 552.2% | -5,704.8% |
| EPS Diluted | -0 | -0.002 | 0.001 | -0.001 |
| % Growth | 95.8% | -500% | 154.5% | – |
| Operating Cash Flow | $0 | -$0 | $0 | -$0 |
| Capital Expenditures | $0 | $0 | $0 | $0 |
| Free Cash Flow | $0 | -$0 | $0 | -$0 |